You just read:

U.S. District Court for the Eastern District of Texas Issues Adverse Trial Decision Concerning RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Patents

News provided by

Allergan plc

Oct 16, 2017, 13:45 ET